DTRF Co-founders Jeanne Whiting and Marlene Portnoy are quoted in an article published by the National Cancer Institute (NCI) on May 1, 2023. Titled, “Nirogacestat May Offer Hope to People with Desmoid Tumors,” by Linda Wang, the article outlines outlines nirogacestat’s impact on desmoid tumors and the NCI’s role in launching a phase 2 study of the drug.
Positive results of the phase 3 DeFi trial allowed SpringWorks Therapeutics to submit a New Drug Application (NDA) for nirogacestat in adults with desmoid tumors, currently under review by the FDA.
Read more here: https://www.cancer.gov/news-events/cancer-currents-blog/2023/nirogacestat-shrinks-desmoid-tumors
